Prediction of pharmacokinetic clearance and potential Drug-Drug interactions for omeprazole in the horse using in vitro systems

References

• Austin RP, Barton P, Mohmed S, Riley RJ. (2005). The binding of drugs to hepatocytes and its relationship to physicochemical properties. Drug Metab Disposition 33:419–25.
   PubMed Web of Science ®Google Scholar
• Begg LM, O’Sullivan CB. (2003). The prevalence and distribution of gastric ulceration in 345 racehorses. Austr Vet J 81: 199–201.
   PubMed Web of Science ®Google Scholar
• Blanchard N, Richert L, Coassolo P, Lave T. (2004). Qualitative and quantitative assessment of drug-drug interaction potential in man, based on Ki, IC50 and inhibitor concentration. Curr Drug Metab 5: 147–56.
   PubMed Web of Science ®Google Scholar
• Blume H, Donath F, Warnke A, Schug BS. (2006). Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf 29:769–84.
   PubMed Web of Science ®Google Scholar
• Brandon EFA, Raap CD, Meijerman I, et al. (2003). An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol Appl Pharmacol 189: 233–46.
   PubMed Web of Science ®Google Scholar
• Burdas KD, WO, Sack, S. Rock 2003. Anatomy of the horse. 4th ed. Germany: Schlütersche.
   Google Scholar
• Diener B, Dietmar U, Beer N, et al. (1993). A method for the cryopresrvation of liver parenchymal cells for studies of xenobiotics. Cryobiology 30:116–27.
   PubMed Web of Science ®Google Scholar
• Dyke TM, Hubbell JA, Sams RA, Hinchcliff KW. (1998). Hepatic blood flow in horses during the recuperative period from maximal exercise. Am J Vet Res 59: 1476–80.
   PubMed Web of Science ®Google Scholar
• Ferdowsian HR, Beck N. (2011). Ethical and scientific considerations regarding animal testing and research. PloS One 6: e24059.
   PubMed Web of Science ®Google Scholar
• Gerbal-Chaloin S, Dume AS, Briolotti P, et al. (2014). The WNT/beta-catenin pathway is a transcriptional regulator of CYP2E1, CYP1A2, and aryl hydrocarbon receptor gene expression in primary human hepatocytes. Mol Pharmacol 86:624–34.
   PubMed Web of Science ®Google Scholar
• Hallifax D, Foster JA, Houston JB. (2010). Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view. Pharmaceutical Res 27(10):2150–61.
   PubMed Web of Science ®Google Scholar
• Ito K, Houston JB. (2004). Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharmaceutical Res 21: 785–92.
   PubMed Web of Science ®Google Scholar
• Jenkins CC, Frazier DL, Blackford JT, et al. (1992). Pharmacokinetics and antisecretory effects of intravenous omeprazole in horses. Equine Vet J 24:84–8.
   PubMed Web of Science ®Google Scholar
• Johns IC, Baxter K, Booler H, et al. (2011). Conjunctival bacterial and fungal flora in healthy horses in the UK. Vet Ophthalmol 14: 195–9.
   PubMed Web of Science ®Google Scholar
• Jouin D, Blanchard N, Alexandre E, et al. (2006). Cryopreserved human hepatocytes in suspension are a convenient high throughput tool for the prediction of metabolic clearance. Eur J Pharmaceutics Biopharmaceutics 63: 347–55.
   PubMed Web of Science ®Google Scholar
• Kanazawa H, Okada A, Matsushima Y, et al. (2002). Determination of omeprazole and its metabolites in human plasma by liquid chromatography–mass spectrometry. J Chromatogr A 949:1–9.
   PubMed Web of Science ®Google Scholar
• Kang BC, Yang CQ, Cho HK, et al. (2002). Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers. Biopharm Drug Dispos 23:77–81.
   PubMed Web of Science ®Google Scholar
• Karam WG, Goldstein JA, Lasker JM, Ghanayem BI. (1996). Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab Dispos 24: 1081–7.
   PubMed Web of Science ®Google Scholar
• McGinnity DF, Soars MG, Urbanowicz RA, Riley RJ. (2004). Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metabol Disposition 32: 1247–53.
   PubMed Web of Science ®Google Scholar
• Nieto J, Snyder J, Vatistas N, Jones J. (2009). Effect of gastric ulceration on physiologic responses to exercise in horses. Am J Vet Res 70:787–95.
   PubMed Web of Science ®Google Scholar
• Park J-y, Kim K-a, Kim S-l. (2003). Chloramphenicol is a potent inhibitor of cytochrome P450 isoforms CYP2C19 and CYP3A4 in human liver microsomes these include: chloramphenicol is a potent inhibitor of cytochrome P450 isoforms CYP2C19 and CYP3A4 in human liver microsomes. Antimicrobial Agents Chemother 47: 3464–9.
   PubMed Web of Science ®Google Scholar
• Regårdh CG, Gabrielsson M, Hoffman KJ, et al. (1985). Pharmacokinetics and metabolism of omeprazole in animals and man–an overview. Scand J Gastroenterol Suppl 20:79–94.
   Google Scholar
• Shibany KA, Tötemeyer S, Pratt SL, Paine SW. (2016). Equine hepatocytes: isolation, cryopreservation, and applications to in vitro drug metabolism studies. Pharma Res Per 4:e00268.
   PubMed Web of Science ®Google Scholar
• Shibany KA, Tötemeyer S, Pratt SL, Paine SW. (2018). The effects of aging on hepatic microsomal scaling factor and hepatocellularity number in the horse. Xenobiotica 48:1237–44.
   PubMed Web of Science ®Google Scholar
• Shin JM, Kim N. (2013). Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motility 19: 25–35.
   PubMed Web of Science ®Google Scholar
• Sykes BW, Underwood C, McGowan CM, Mills PC. (2015). Pharmacokinetics of intravenous, plain oral and enteric- coated oral omeprazole in the horse. J Vet Pharmacol Therapeutics 38:130–6.
   PubMed Web of Science ®Google Scholar
• Sykes MJ, Sorich MJ, Miners JO. (2006). Molecular modeling approaches for the prediction of the nonspecific binding of drugs to hepatic microsomes. J Chem Inf Model 46:2661–73.
   PubMed Web of Science ®Google Scholar
• Toutain PL, Lassourd V. (2002). Pharmacokinetic/pharmacodynamic approach to assess irrelevant plasma or urine drug concentrations in post-competition samples for drug control in the horse. Equine Vet J 34:242–9.
   PubMed Web of Science ®Google Scholar
• Videla R, Andrews FM. (2009). New perspectives in equine gastric ulcer syndrome. Vet Clinics North America Equine Prac 25:283–301.
   PubMed Web of Science ®Google Scholar